James F Chmiel MD

Pediatric Pulmonology•Indianapolis, IN

Cystic Fibrosis Pulmonology, Pediatric Asthma Pulmonology, Pediatric Bronchoscopy

Professor of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine

Join to View Full Profile

705 Riley Hospital Dr# 4270Indianapolis, IN 46202
Phone+1 317-948-7208
Fax+1 317-944-7247

Education & Training

Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalFellowship, Pediatric Pulmonology, 1995 - 1998
McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 1991 - 1994
University of Michigan Medical SchoolClass of 1991

Certifications & Licensure

IN State Medical License 2019 - 2027
OH State Medical License 1995 - 2019
IL State Medical License 1991 - 1996
American Board of Pediatrics Pediatric Pulmonology

Clinical Trials

Assessment of Inflammatory Mediators (AIM) Start of enrollment: 2004 Aug 01
Completed
Not Applicable
Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations Start of enrollment: 2006 Sep 01
Completed
Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma Start of enrollment: 2011 Apr 01
Completed
Phase 3
Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids. Start of enrollment: 2011 Mar 01
Completed
Phase 3
Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation Start of enrollment: 2011 Apr 01
Completed
Not Applicable
Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study) Start of enrollment: 2011 Oct 01
Completed
Phase 3
Severe Asthma Research Program
ACTIVE_NOT_RECRUITING
Airway Redox and Gender Determinants in Severe Asthma
ACTIVE_NOT_RECRUITING
IL-17 Neutrophils in CF Lung Inflammation Start of enrollment: 2014 Feb 01
Completed
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis Start of enrollment: 2014 Jun 01
Completed
Phase 3
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation Start of enrollment: 2015 Nov 01
Completed
Phase 2
Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) Start of enrollment: 2016 Oct 21
Completed
Phase 4
Pulmonary Vascular Disease in CF Start of enrollment: 2020 Jul 29
RECRUITING
Join now to see all

Publications & Presentations

PubMed

Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis.
Natalie E West, Michael W Konstan, Patrick A Flume, Donald R VanDevanter, Amalia Magaret
Journal of Cystic Fibrosis. 2025-07-01
Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR.
Yunjie Huang, Jorge Moises Gonzales Cordova, Sarah Penrod, Lisa Lynn Bendy, Pi Chun Cheng
International Journal of Molecular Sciences. 2025-05-31
Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis.
Michael W Konstan, Deepika Polineni, James F Chmiel, Lara Bilodeau, Peter G Middleton
Journal of Cystic Fibrosis. 2025-01-01

Press Mentions

Researchers Awarded $12 Million to Pursue Personalized Therapies for Severe AsthmaOctober 18th, 2021
University Hospitals Rainbow Babies & Children’s Hospital to Study African Americans Response to Asthma MedicationsFebruary 12th, 2016

James F Chmiel MD

Dr. Chmiel is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.